[ABE-L] Fwd: Seminários PPGEEA

Qui Nov 6 15:35:33 -03 2025

---------- Forwarded message ---------
From: Fábio Prataviera <fabio_prataviera em usp.br>
Date: Thu, Nov 6, 2025 at 3:33 PM
Subject: Re: Seminários PPGEEA

*Prezados**(as)**, boa tarde!*

Segue o link de acesso ao seminário ministrado pelo Professor
*Geert Molenberghs.*

https://www.youtube.com/@lce-esalq/streams

Atenciosamente,
Fábio Prataviera
Universidade de São Paulo
Escola Superior de Agricultura "Luiz de Queiroz"
Departamento de Ciências Exatas
Telefone: +55 (19) 3447-8905
ORCID: https://orcid.org/0000-0001-8190-1086
CV: http://lattes.cnpq.br/3225385085167748

Em qui., 6 de nov. de 2025 às 14:02, Rodrigo Domiciano Marques <
marques_rd em usp.br> escreveu:

> Boa tarde, Fábio.
> Temos o link para o seminário de hoje?
>
> Em seg., 3 de nov. de 2025 às 13:56, Fábio Prataviera <
> fabio_prataviera em usp.br> escreveu:
>
>> *Prezados**(as)**, bom dia!*
>>
>> Dando continuidade à programação de seminários do PPGEEA, nesta semana
>> teremos a apresentação do Professor *Geert Molenberghs*, que será
>> transmitida* no LAB A*, das *14h *às* 15h,* no dia* 06/11/2025*.
>>
>> Segue, abaixo, uma breve biografia do palestrante, bem como o título e o
>> resumo de sua apresentação.
>>
>>
>> *Breve Biografia*
>>
>> Geert Molenberghs is professor at the Faculty of Medicine at KU Leuven
>> and at Hasselt University. He teaches Longitudinal Data Analysis,
>> Statistical Consulting, and Sampling Theory among other courses. He is
>> chair of the Leuven Statistics Research Centre (LStat).
>> Prof. Molenberghs obtained his PhD in Statistics in 1993. The title of
>> his research project was “A Full Maximum Likelihood Method for the Analysis
>> of Multivariate Ordered Categorical Data”. His supervisors were Prof.
>> Rousseeuw and Prof. Lesaffre. In 2004, he was appointed full professor at
>> Hasselt University. Three years later, he was appointed part-time professor
>> at KU Leuven.
>> Throughout the years, prof. Molenberghs has been the (co-)advisor for
>> many PhD researchers and master students. He has also been a member of many
>> expert committees and professional societies such as the Royal Statistical
>> Society (UK), the International Society for Clinical Biostatistics and the
>> Psychometric Society. Among other boards, he’s an Advisory Board Member of
>> Biostatistics and the Executive Editor of Biometrics. Lastly, prof.
>> Molenberghs is a consultant for many partners in diverse fields including
>> Pfizer, the Universiteit Antwerpen, and Ziekenhuis Oost Limburg.
>> *Título*
>> *The statistical evaluation of surrogate endpoints in clinical trials –
>> and beyond *
>>
>> *Resumo*
>> Both humanitarian and commercial considerations have spurred intensive
>> search for methods to reduce the time and cost required to develop new
>> therapies. The identification and use of surrogate endpoints, i.e. measures
>> that can replace or supplement other endpoints in evaluations of
>> experimental treatments or interventions, is a general strategy that has
>> stimulated much enthusiasm. Surrogate endpoints are useful when they can be
>> measured earlier, more conveniently, or more frequently than the
>> "true" endpoints of primary interest. Regulatory agencies around
>> the globe, particularly in the United States, Europe, and Japan,
>> are introducing provisions and policies relating to the use of surrogate
>> endpoints in registration studies. But how can one establish the adequacy
>> of a surrogate, in the sense that treatment effectiveness on the surrogate
>> will accurately predict treatment effect on the intended, and more
>> important, true outcome? What kind of evidence is needed, and what
>> statistical methods portray that evidence most appropriately? The
>> definition of validity, as well as formal sets of criteria, have been
>> proposed, including use of the proportion explained, jointly the
>> within-treatment partial association of true and surrogate responses, and
>> the treatment effect on the surrogate relative to that on the true outcome.
>> In a multi-centre setting, these quantities can be generalized
>> to individual-level and trial-level measures of surrogacy. Consequently, a
>> meta-analytic framework studying surrogacy at both the trial and
>> individual-patient levels has been proposed. A number of variations of
>> this theme have been developed, depending on the type of endpoint for the
>> true and surrogate endpoint and on the focus of the evaluation exercise.
>> Recent developments have been based on information theory,
>> principal stratification, and causal inference. The field of surrogate
>> marker evaluation, in turn, has sparked a number of developments towards
>> efficient estimation in complex hierarchical models.
>>
>> *Contamos com a participação de todos! *
>>
>> Abraço
>>
>> Atenciosamente,
>> Fábio Prataviera
>> Universidade de São Paulo
>> Escola Superior de Agricultura "Luiz de Queiroz"
>> Departamento de Ciências Exatas
>> Telefone: +55 (19) 3447-8905
>> ORCID: https://orcid.org/0000-0001-8190-1086
>> CV: http://lattes.cnpq.br/3225385085167748
>>
>
>
> --
> Atenciosamente
> Rodrigo Domiciano Marques
> Doutorando em Estatística e Experimentação Agronômica - ESALQ/USP
> Engenheiro Agrônomo - CLM/UENP
>
>
-------------- Próxima Parte ----------
Um anexo em HTML foi limpo...
URL: <http://lists.ime.usp.br/pipermail/abe/attachments/20251106/bec80bda/attachment-0003.htm>